{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:30:24Z","timestamp":1788215424669,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jcf.2024.01.003","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T19:15:17Z","timestamp":1718219717000},"page":"653-657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacologic contraception methods for people with cystic fibrosis: A practical review for clinicians"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1089-7531","authenticated-orcid":false,"given":"E. Claire","family":"Elson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4103-6192","authenticated-orcid":false,"given":"Taylor","family":"Imburgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4285-1260","authenticated-orcid":false,"given":"Kevin","family":"Lonabaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1362-4708","authenticated-orcid":false,"given":"Lindsey","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4492-7249","authenticated-orcid":false,"given":"Nicole E.","family":"Omecene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1577-6656","authenticated-orcid":false,"given":"Shannon M.","family":"Rotolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.01.003_bib0001","unstructured":"Cystic Fibrosis Foundation. About cystic fibrosis. https:\/\/www.cff.org\/intro-cf\/about-cystic-fibrosis; 2023 [accessed 23 June 2023]."},{"key":"10.1016\/j.jcf.2024.01.003_bib0002","unstructured":"Cystic Fibrosis Foundation. 2022 cystic fibrosis foundation patient registry highlights [Bethesda, MD]; 2023."},{"issue":"10212","key":"10.1016\/j.jcf.2024.01.003_bib0003","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomized, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2024.01.003_bib0004","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jcf.2024.01.003_bib0005","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jcf.2018.10.009","article-title":"Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age","volume":"18","author":"Shteinberg","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2024.01.003_bib0006","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/jpm11050418","article-title":"Fertility, pregnancy, and lactation considerations for women with CF in the CFTR modulator era","volume":"11","author":"Jain","year":"2021","journal-title":"J Pers Med"},{"issue":"3","key":"10.1016\/j.jcf.2024.01.003_bib0007","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jcf.2020.12.011","article-title":"Elexacaftor\/tezacaftor\/ivacaftor resolves subfertility in females with CF: a two center case series","volume":"20","author":"O'Connor","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.01.003_bib0008","doi-asserted-by":"crossref","unstructured":"Hsu Roe A., Traxler S.T., Hadjiliadis D., Samuel M.D., Schreiber C.A. Contraceptive choices and preferences in a cohort of women with cystic fibrosis. Respir Med 2016;121:1\u20133. j.rmed.2016.10.012.","DOI":"10.1016\/j.rmed.2016.10.012"},{"issue":"2","key":"10.1016\/j.jcf.2024.01.003_bib0009","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jcf.2022.09.013","article-title":"Sexual and reproductive health experiences and care of adult women with cystic fibrosis","volume":"22","author":"Kazmerski","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.01.003_bib0010","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jcf.2017.08.009","article-title":"Sexual and reproductive health care utilization and preferences reported by young women with cystic fibrosis","volume":"17","author":"Kazmerski","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.01.003_bib0011","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.contraception.2020.02.006","article-title":"Contraceptive use among women with cystic fibrosis: a pilot study linking reproductive health questions to the Cystic Fibrosis Foundation National Patient Registry","volume":"101","author":"Godfrey","year":"2020","journal-title":"Contraception"},{"issue":"3","key":"10.1016\/j.jcf.2024.01.003_bib0012","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1743-6109.2008.01049.x","article-title":"Sexual and reproductive health knowledge in cystic fibrosis female patients and their parents","volume":"6","author":"Korzeniewska","year":"2009","journal-title":"J Sex Med"},{"issue":"8","key":"10.1016\/j.jcf.2024.01.003_bib0013","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ppul.24015","article-title":"Perspectives of adolescent girls with cystic fibrosis and parents on disease-specific sexual and reproductive health education","volume":"53","author":"Kazmerski","year":"2018","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jcf.2024.01.003_bib0014","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1183\/09031936.00018712","article-title":"Oral contraceptives do not appear to affect cystic fibrosis disease severity","volume":"41","author":"Kernan","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2024.01.003_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2016.10.012","article-title":"Contraceptive choices and preferences in a cohort of women with cystic fibrosis","volume":"121","author":"Roe","year":"2016","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.jcf.2024.01.003_bib0016","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/ppul.25322","article-title":"Reproductive health counseling and contraceptive use in adolescents with cystic fibrosis","volume":"56","author":"Hernandez","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.jcf.2024.01.003_bib0017","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/01.NAJ.0000654304.29632.a7","article-title":"CE: an evidence-based update on contraception","volume":"120","author":"Britton","year":"2020","journal-title":"Am J Nurs"},{"key":"10.1016\/j.jcf.2024.01.003_bib0018","article-title":"Use of estrogen supplementation is associated with higher quality of life scores in women with cystic fibrosis","volume":"27","author":"Wu","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"issue":"1","key":"10.1016\/j.jcf.2024.01.003_bib0019","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.contraception.2015.07.007","article-title":"Contraception in women with cystic fibrosis: a systematic review of the literature","volume":"93","author":"Roe","year":"2016","journal-title":"Contraception"},{"issue":"7","key":"10.1016\/j.jcf.2024.01.003_bib0020","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1513\/AnnalsATS.202008-1064OC","article-title":"A prospective study of the effects of sex hormones on lung function and inflammation in women with cystic fibrosis","volume":"18","author":"Holtrop","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2024.01.003_bib0021","article-title":"Oral ethinyl estradiol treatment in women with cystic fibrosis is associated with lower bone mineral density","volume":"20","author":"Wu","year":"2020","journal-title":"J Clin Transl Endocrinol"},{"issue":"Suppl 45","key":"10.1016\/j.jcf.2024.01.003_bib0022","first-page":"7","article-title":"The sexual health of adolescents with cystic fibrosis","volume":"98","author":"Roberts","year":"2005","journal-title":"J R Soc Med"},{"issue":"6","key":"10.1016\/j.jcf.2024.01.003_bib0023","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jcf.2022.09.002","article-title":"Drug-induced acne with elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis","volume":"21","author":"Hudson","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.01.003_bib0024","article-title":"Analysis of reports of unintended pregnancies associated with the combined use of non-enzyme-inducing antibiotics and hormonal contraceptives","author":"Aronson","year":"2020","journal-title":"BMJ Evid Based Med"},{"issue":"818","key":"10.1016\/j.jcf.2024.01.003_bib0025","first-page":"102","article-title":"Pill method failures","volume":"100","author":"Sparrow","year":"1987","journal-title":"N Z Med J"},{"issue":"5 pt 1","key":"10.1016\/j.jcf.2024.01.003_bib0026","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0190-9622(97)80322-2","article-title":"Krishnarao. Oral contraceptive failure rates and oral antibiotics","volume":"36","author":"Helms","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jcf.2024.01.003_bib0027","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1067\/mjd.2002.120448","article-title":"Oral contraceptive efficacy and antibiotic interaction: a myth debunked","volume":"46","author":"Archer","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jcf.2024.01.003_bib0028","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1097\/AOG.0000000000003072","article-title":"ACOG practice bulletin No. 206: Use of hormonal contraception in women with coexisting medical conditions","volume":"133","author":"Allen","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.jcf.2024.01.003_bib0029","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jcph.377","article-title":"Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein","volume":"55","author":"Robertson","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jcf.2024.01.003_bib0030","unstructured":"Orkambi\u00ae [package insert]. Boston (MA): Vertex Pharmaceuticals Inc; 2015 Jul 6."},{"key":"10.1016\/j.jcf.2024.01.003_bib0031","unstructured":"First progestogen-only contraceptive pills to be available to purchase from pharmacies. GOV.UK. Accessed July 7, 2023. https:\/\/www.gov.uk\/government\/news\/first-progesterone-only-contraceptive-pills-to-be-available-to-purchase-from-pharmacies."},{"key":"10.1016\/j.jcf.2024.01.003_bib0032","unstructured":"Commissioner O of the. FDA approves first nonprescription daily oral contraceptive. FDA. Published July 13, 2023. Accessed July 14, 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-nonprescription-daily-oral-contraceptive."},{"issue":"6","key":"10.1016\/j.jcf.2024.01.003_bib0033","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.contraception.2012.05.018","article-title":"User characteristics and out-of-pocket expenditures for progestin-only versus combined oral contraceptives","volume":"86","author":"Liang","year":"2012","journal-title":"Contraception"},{"issue":"11","key":"10.1016\/j.jcf.2024.01.003_bib0034","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1093\/humrep\/dev217","article-title":"Contraceptive practices and cervical screening in women with cystic fibrosis","volume":"30","author":"Rousset Jablonski","year":"2015","journal-title":"Hum Reprod"},{"issue":"11","key":"10.1016\/j.jcf.2024.01.003_bib0035","article-title":"Progestin-only pills for contraception","author":"Grimes","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcf.2024.01.003_bib0036","series-title":"Contraception","first-page":"873","author":"Schreiber","year":"2009"},{"key":"10.1016\/j.jcf.2024.01.003_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2022.109925","article-title":"Effectiveness and efficacy rates of progestin-only pills: a comprehensive literature review","volume":"119","author":"Zuniga","year":"2023","journal-title":"Contraception"},{"issue":"9","key":"10.1016\/j.jcf.2024.01.003_bib0038","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1055\/a-1471-4408","article-title":"Oral progestins in hormonal contraception: importance and future perspectives of a new progestin only-pill containing 4mg drospirenone","volume":"81","author":"Romer","year":"2021","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"5","key":"10.1016\/j.jcf.2024.01.003_bib0039","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0002-9378(99)70120-1","article-title":"The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices","volume":"181","author":"Rivera","year":"1999","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.jcf.2024.01.003_bib0040","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1783\/147118908786000451","article-title":"Ovulation incidence with oral contraceptives: a literature review","volume":"34","author":"Milsom","year":"2008","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.jcf.2024.01.003_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2023.109978","article-title":"A commentary on progestin-only pills and the \u201cthree-hour window\u201d guidelines: timing of ingestion and mechanisms of action","volume":"122","author":"Wollum","year":"2023","journal-title":"Contraception"},{"key":"10.1016\/j.jcf.2024.01.003_bib0042","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.contraception.2022.04.006","article-title":"Adherence among a cohort taking progestin-only pills prescribed by a healthcare provider: results of the BENCHMARK study","volume":"112","author":"Bradford","year":"2022","journal-title":"Contraception"},{"issue":"4","key":"10.1016\/j.jcf.2024.01.003_bib0043","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.contraception.2015.12.007","article-title":"Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake","volume":"93","author":"Duijkers","year":"2016","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.jcf.2024.01.003_bib0044","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.contraception.2004.07.016","article-title":"Maintenance of ovulation inhibition with the 75-microg desogestrel-only contraceptive pill (Cerazette) after scheduled 12-h delays in tablet intake","volume":"71","author":"Korver","year":"2005","journal-title":"Contraception"},{"issue":"15","key":"10.1016\/j.jcf.2024.01.003_bib0045","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.3390\/jcm11154634","article-title":"Bleeding patterns of oral contraceptives with a cyclic dosing regimen: an overview","volume":"11","author":"Archer","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcf.2024.01.003_bib0046","doi-asserted-by":"crossref","DOI":"10.1007\/s00404-019-05340-4","article-title":"A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone-only pill 4mg over nine cycles in comparison with desogestrel 0.075mg","author":"Palacios","year":"2019","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"10.1016\/j.jcf.2024.01.003_bib0047","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12905-020-01080-9","article-title":"Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4\u2009mg drospirenone alone in a 24\/4 regime","volume":"20","author":"Palacios","year":"2020","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.jcf.2024.01.003_bib0048","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.14309\/01.ajg.0000589680.24021.2f","article-title":"37\u2003depot medroxyprogesterone acetate in the management of recurrent acute pancreatitis in patients with cystic fibrosis gene mutations","volume":"114","author":"Haydek","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jcf.2024.01.003_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100800","article-title":"Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: findings from a randomised, multicentre, open-label trial","volume":"34","author":"Beksinska","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"8","key":"10.1016\/j.jcf.2024.01.003_bib0050","article-title":"Progestin-only contraceptives: effects on weight","volume":"2016","author":"Lopez","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.jcf.2024.01.003_bib0051","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/13625187.2019.1709963","article-title":"Depo-medroxyprogesterone acetate, weight gain and amenorrhea among obese adolescent and adult women","volume":"25","author":"Sims","year":"2020","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"5","key":"10.1016\/j.jcf.2024.01.003_bib0052","doi-asserted-by":"crossref","first-page":"326","DOI":"10.14740\/jocmr3792","article-title":"Prevalence of documented excessive weight gain among adolescent girls and young women using Depot medroxyprogesterone acetate","volume":"11","author":"Jirakittidul","year":"2019","journal-title":"J Clin Med Res"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2024.01.003_bib0053","first-page":"S40","article-title":"Overweight and cystic fibrosis: an unexpected challenge","volume":"57","author":"Gabel","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.01.003_bib0054","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1471-2466-14-165","article-title":"Subcutaneous implant with etonogestrel (Implanon\u00ae) for catamenial exacerbations in a patient with cystic fibrosis: a case report","volume":"14","author":"Lamas","year":"2014","journal-title":"BMC Pulm Med"},{"issue":"4","key":"10.1016\/j.jcf.2024.01.003_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6504a1","article-title":"U.S. selected practice recommendations for contraceptive use, 2016","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"issue":"2","key":"10.1016\/j.jcf.2024.01.003_bib0056","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-007252","article-title":"Long-acting reversible contraception: specific issues for adolescents","volume":"146","author":"Menon","year":"2020","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.jcf.2024.01.003_bib0057","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1783\/147118909788708075","article-title":"Provision of contraception services and advice for women with cystic fibrosis","volume":"35","author":"Gatiss","year":"2009","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.jcf.2024.01.003_bib0058","doi-asserted-by":"crossref","first-page":"m3966","DOI":"10.1136\/bmj.m3966","article-title":"Pregravid contraceptive use and fecundability: prospective cohort study","volume":"371","author":"Yland","year":"2020","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.jcf.2024.01.003_bib0059","article-title":"Return of fertility after discontinuation of contraception: a systematic review and meta-analysis","volume":"3","author":"Girum","year":"2018","journal-title":"Contracept Reprod Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:07:05Z","timestamp":1783019225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1569199324000031"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.01.003","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic contraception methods for people with cystic fibrosis: A practical review for clinicians","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}